Literature DB >> 33934921

Refining biomarker evaluation in ASD.

James C McPartland1.   

Abstract

This commentary reflects on reasonable biomarker expectations in ASD by addressing three key questions: What is a biomarker? What is required for a biomarker in ASD? How can biomarkers be useful in ASD? In addressing these queries, a path forward emerges based on clear definition of the objective for any given ASD biomarker and evaluation of each biomarker relative to current best practices.
Copyright © 2021. Published by Elsevier B.V.

Entities:  

Keywords:  Autism spectrum disorder; Biomarkers; Clinical trials; Endpoints

Mesh：

Substances：

Year:  2021        PMID： 33934921      PMCID： PMC8238819          DOI： 10.1016/j.euroneuro.2021.03.023

Source DB:  PubMed          Journal:  Eur Neuropsychopharmacol        ISSN： 0924-977X            Impact factor:   5.415


  7 in total

1.  Placebo-like response in absence of treatment in children with Autism.

Authors:  Rebecca M Jones; Caroline Carberry; Amarelle Hamo; Catherine Lord
Journal:  Autism Res       Date:  2017-04-12       Impact factor: 5.216

2.  Can the N170 Be Used as an Electrophysiological Biomarker Indexing Face Processing Difficulties in Autism Spectrum Disorder?

Authors:  Sofie Vettori; Corentin Jacques; Bart Boets; Bruno Rossion
Journal:  Biol Psychiatry Cogn Neurosci Neuroimaging       Date:  2018-11-01

3.  Biomarkers of Face Perception in Autism Spectrum Disorder: Time to Shift to Fast Periodic Visual Stimulation With Electroencephalography?

Authors:  Bruno Rossion
Journal:  Biol Psychiatry Cogn Neurosci Neuroimaging       Date:  2020-03

Review 4.  Considerations in biomarker development for neurodevelopmental disorders.

Authors:  James C McPartland
Journal:  Curr Opin Neurol       Date:  2016-04       Impact factor: 5.710

5.  The Unfulfilled Promise of the N170 as a Social Biomarker.

Authors:  Alexandra P Key; Blythe A Corbett
Journal:  Biol Psychiatry Cogn Neurosci Neuroimaging       Date:  2019-09-13

Review 6.  Drug development for Autism Spectrum Disorder (ASD): Progress, challenges, and future directions.

Authors:  James T McCracken; Evdokia Anagnostou; Celso Arango; Geraldine Dawson; Tiffany Farchione; Valentina Mantua; James McPartland; Declan Murphy; Gahan Pandina; Jeremy Veenstra-VanderWeele
Journal:  Eur Neuropsychopharmacol       Date:  2021-06-19       Impact factor: 5.415

7.  The Autism Biomarkers Consortium for Clinical Trials (ABC-CT): Scientific Context, Study Design, and Progress Toward Biomarker Qualification.

Authors:  James C McPartland; Raphael A Bernier; Shafali S Jeste; Geraldine Dawson; Charles A Nelson; Katarzyna Chawarska; Rachel Earl; Susan Faja; Scott P Johnson; Linmarie Sikich; Cynthia A Brandt; James D Dziura; Leon Rozenblit; Gerhard Hellemann; April R Levin; Michael Murias; Adam J Naples; Michael L Platt; Maura Sabatos-DeVito; Frederick Shic; Damla Senturk; Catherine A Sugar; Sara J Webb
Journal:  Front Integr Neurosci       Date:  2020-04-09
  7 in total
  2 in total

1.  The autism biomarkers consortium for clinical trials: evaluation of a battery of candidate eye-tracking biomarkers for use in autism clinical trials.

Authors:  Frederick Shic; Adam J Naples; Erin C Barney; Shou An Chang; Beibin Li; Takumi McAllister; Minah Kim; Kelsey J Dommer; Simone Hasselmo; Adham Atyabi; Quan Wang; Gerhard Helleman; April R Levin; Helen Seow; Raphael Bernier; Katarzyna Charwaska; Geraldine Dawson; James Dziura; Susan Faja; Shafali Spurling Jeste; Scott P Johnson; Michael Murias; Charles A Nelson; Maura Sabatos-DeVito; Damla Senturk; Catherine A Sugar; Sara J Webb; James C McPartland
Journal:  Mol Autism       Date:  2022-03-21       Impact factor: 6.476

2.  Brief Report: Preliminary Evidence of the N170 as a Biomarker of Response to Treatment in Autism Spectrum Disorder.

Authors:  Shashwat Kala; Max J Rolison; Dominic A Trevisan; Adam J Naples; Kevin Pelphrey; Pamela Ventola; James C McPartland
Journal:  Front Psychiatry       Date:  2021-06-29       Impact factor: 4.157
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.